The future is now: Model-based clinical trial design for Alzheimer's disease
Failures in trials for Alzheimer's disease (AD) may be attributable to inadequate dosing, population selection, drug inefficacy, or insufficient design optimization. The Coalition Against Major Diseases (CAMD) was formed in 2008 to develop drug development tools (DDT) to expedite drug developme...
Gespeichert in:
| Veröffentlicht in: | Clinical pharmacology and therapeutics 2015-03, Vol.97 (3), p.210-214 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 214 |
|---|---|
| container_issue | 3 |
| container_start_page | 210 |
| container_title | Clinical pharmacology and therapeutics |
| container_volume | 97 |
| creator | Romero, K Ito, K Rogers, JA Polhamus, D Qiu, R Stephenson, D Mohs, R Lalonde, R Sinha, V Wang, Y Brown, D Isaac, M Vamvakas, S Hemmings, R Pani, L Bain, LJ Corrigan, B |
| description | Failures in trials for Alzheimer's disease (AD) may be attributable to inadequate dosing, population selection, drug inefficacy, or insufficient design optimization. The Coalition Against Major Diseases (CAMD) was formed in 2008 to develop drug development tools (DDT) to expedite drug development for AD and Parkinson's disease.1 CAMD led a process that successfully advanced a clinical trial simulation (CTS) tool for AD through the formal regulatory review process at the US Food and Drug Administration (FDA) and European Medicines Agency (EMA). |
| doi_str_mv | 10.1002/cpt.16 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6463482</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1657325950</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4386-39c3b4ba876e1fb83fdd4f21613e885a09f26ac2061cd0e9fa952d75523e03eb3</originalsourceid><addsrcrecordid>eNp1kE1v1DAQhi0EokuBn4B84uOQ4o_YsTkglRVtQUtBaFElLpZjj7um2WSxE9ry62vYsoIDF4-seeaZ0YvQY0oOKCHspduMB1TeQTMqOKuk4OIumhFCdKUZl3voQc7fyrfWSt1He0xIqWktZmixXAEO0zglwDHjfrh8hT8MHrqqtRk8dl3so7MdHlMsr4ccz3schoQPu58riGtIzzL2MUPBH6J7wXYZHt3WffTl6O1yflItPh6_mx8uKldzJSuuHW_r1qpGAg2t4sH7OjAqKQelhCU6MGkdI5I6T0AHqwXzjRCMA-HQ8n30euvdTO0avIN-TLYzmxTXNl2bwUbzb6ePK3M-_DCylrxWrAie3wrS8H2CPJp1zA66zvYwTNlQKRrOhBakoE-3qEtDzgnCbg0l5lf0pkRfBgr45O-jdtifrAvwYgtcxg6u_6Mx80_L37Jqy8Y8wtWOtenCyIY3wpydHpvP89P3X8_eKKP4DesNm_8</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1657325950</pqid></control><display><type>article</type><title>The future is now: Model-based clinical trial design for Alzheimer's disease</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Romero, K ; Ito, K ; Rogers, JA ; Polhamus, D ; Qiu, R ; Stephenson, D ; Mohs, R ; Lalonde, R ; Sinha, V ; Wang, Y ; Brown, D ; Isaac, M ; Vamvakas, S ; Hemmings, R ; Pani, L ; Bain, LJ ; Corrigan, B</creator><creatorcontrib>Romero, K ; Ito, K ; Rogers, JA ; Polhamus, D ; Qiu, R ; Stephenson, D ; Mohs, R ; Lalonde, R ; Sinha, V ; Wang, Y ; Brown, D ; Isaac, M ; Vamvakas, S ; Hemmings, R ; Pani, L ; Bain, LJ ; Corrigan, B ; Alzheimer's Disease Neuroimaging Initiative ; Coalition Against Major Diseases ; Alzheimer's Disease Neuroimaging Initiative for the Coalition Against Major Diseases</creatorcontrib><description>Failures in trials for Alzheimer's disease (AD) may be attributable to inadequate dosing, population selection, drug inefficacy, or insufficient design optimization. The Coalition Against Major Diseases (CAMD) was formed in 2008 to develop drug development tools (DDT) to expedite drug development for AD and Parkinson's disease.1 CAMD led a process that successfully advanced a clinical trial simulation (CTS) tool for AD through the formal regulatory review process at the US Food and Drug Administration (FDA) and European Medicines Agency (EMA).</description><identifier>ISSN: 0009-9236</identifier><identifier>EISSN: 1532-6535</identifier><identifier>DOI: 10.1002/cpt.16</identifier><identifier>PMID: 25669145</identifier><language>eng</language><publisher>United States: Blackwell Publishing Ltd</publisher><subject>Alzheimer Disease - drug therapy ; Clinical Trials as Topic - methods ; Computer Simulation ; Drug Approval - legislation & jurisprudence ; Drug Approval - methods ; Europe ; Humans ; United States ; United States Food and Drug Administration - legislation & jurisprudence</subject><ispartof>Clinical pharmacology and therapeutics, 2015-03, Vol.97 (3), p.210-214</ispartof><rights>2014 American Society for Clinical Pharmacology and Therapeutics</rights><rights>2014 American Society for Clinical Pharmacology and Therapeutics.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4386-39c3b4ba876e1fb83fdd4f21613e885a09f26ac2061cd0e9fa952d75523e03eb3</citedby><cites>FETCH-LOGICAL-c4386-39c3b4ba876e1fb83fdd4f21613e885a09f26ac2061cd0e9fa952d75523e03eb3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fcpt.16$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fcpt.16$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>230,314,776,780,881,1411,27901,27902,45550,45551</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25669145$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Romero, K</creatorcontrib><creatorcontrib>Ito, K</creatorcontrib><creatorcontrib>Rogers, JA</creatorcontrib><creatorcontrib>Polhamus, D</creatorcontrib><creatorcontrib>Qiu, R</creatorcontrib><creatorcontrib>Stephenson, D</creatorcontrib><creatorcontrib>Mohs, R</creatorcontrib><creatorcontrib>Lalonde, R</creatorcontrib><creatorcontrib>Sinha, V</creatorcontrib><creatorcontrib>Wang, Y</creatorcontrib><creatorcontrib>Brown, D</creatorcontrib><creatorcontrib>Isaac, M</creatorcontrib><creatorcontrib>Vamvakas, S</creatorcontrib><creatorcontrib>Hemmings, R</creatorcontrib><creatorcontrib>Pani, L</creatorcontrib><creatorcontrib>Bain, LJ</creatorcontrib><creatorcontrib>Corrigan, B</creatorcontrib><creatorcontrib>Alzheimer's Disease Neuroimaging Initiative</creatorcontrib><creatorcontrib>Coalition Against Major Diseases</creatorcontrib><creatorcontrib>Alzheimer's Disease Neuroimaging Initiative for the Coalition Against Major Diseases</creatorcontrib><title>The future is now: Model-based clinical trial design for Alzheimer's disease</title><title>Clinical pharmacology and therapeutics</title><addtitle>Clin. Pharmacol. Ther</addtitle><description>Failures in trials for Alzheimer's disease (AD) may be attributable to inadequate dosing, population selection, drug inefficacy, or insufficient design optimization. The Coalition Against Major Diseases (CAMD) was formed in 2008 to develop drug development tools (DDT) to expedite drug development for AD and Parkinson's disease.1 CAMD led a process that successfully advanced a clinical trial simulation (CTS) tool for AD through the formal regulatory review process at the US Food and Drug Administration (FDA) and European Medicines Agency (EMA).</description><subject>Alzheimer Disease - drug therapy</subject><subject>Clinical Trials as Topic - methods</subject><subject>Computer Simulation</subject><subject>Drug Approval - legislation & jurisprudence</subject><subject>Drug Approval - methods</subject><subject>Europe</subject><subject>Humans</subject><subject>United States</subject><subject>United States Food and Drug Administration - legislation & jurisprudence</subject><issn>0009-9236</issn><issn>1532-6535</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kE1v1DAQhi0EokuBn4B84uOQ4o_YsTkglRVtQUtBaFElLpZjj7um2WSxE9ry62vYsoIDF4-seeaZ0YvQY0oOKCHspduMB1TeQTMqOKuk4OIumhFCdKUZl3voQc7fyrfWSt1He0xIqWktZmixXAEO0zglwDHjfrh8hT8MHrqqtRk8dl3so7MdHlMsr4ccz3schoQPu58riGtIzzL2MUPBH6J7wXYZHt3WffTl6O1yflItPh6_mx8uKldzJSuuHW_r1qpGAg2t4sH7OjAqKQelhCU6MGkdI5I6T0AHqwXzjRCMA-HQ8n30euvdTO0avIN-TLYzmxTXNl2bwUbzb6ePK3M-_DCylrxWrAie3wrS8H2CPJp1zA66zvYwTNlQKRrOhBakoE-3qEtDzgnCbg0l5lf0pkRfBgr45O-jdtifrAvwYgtcxg6u_6Mx80_L37Jqy8Y8wtWOtenCyIY3wpydHpvP89P3X8_eKKP4DesNm_8</recordid><startdate>201503</startdate><enddate>201503</enddate><creator>Romero, K</creator><creator>Ito, K</creator><creator>Rogers, JA</creator><creator>Polhamus, D</creator><creator>Qiu, R</creator><creator>Stephenson, D</creator><creator>Mohs, R</creator><creator>Lalonde, R</creator><creator>Sinha, V</creator><creator>Wang, Y</creator><creator>Brown, D</creator><creator>Isaac, M</creator><creator>Vamvakas, S</creator><creator>Hemmings, R</creator><creator>Pani, L</creator><creator>Bain, LJ</creator><creator>Corrigan, B</creator><general>Blackwell Publishing Ltd</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>201503</creationdate><title>The future is now: Model-based clinical trial design for Alzheimer's disease</title><author>Romero, K ; Ito, K ; Rogers, JA ; Polhamus, D ; Qiu, R ; Stephenson, D ; Mohs, R ; Lalonde, R ; Sinha, V ; Wang, Y ; Brown, D ; Isaac, M ; Vamvakas, S ; Hemmings, R ; Pani, L ; Bain, LJ ; Corrigan, B</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4386-39c3b4ba876e1fb83fdd4f21613e885a09f26ac2061cd0e9fa952d75523e03eb3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Alzheimer Disease - drug therapy</topic><topic>Clinical Trials as Topic - methods</topic><topic>Computer Simulation</topic><topic>Drug Approval - legislation & jurisprudence</topic><topic>Drug Approval - methods</topic><topic>Europe</topic><topic>Humans</topic><topic>United States</topic><topic>United States Food and Drug Administration - legislation & jurisprudence</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Romero, K</creatorcontrib><creatorcontrib>Ito, K</creatorcontrib><creatorcontrib>Rogers, JA</creatorcontrib><creatorcontrib>Polhamus, D</creatorcontrib><creatorcontrib>Qiu, R</creatorcontrib><creatorcontrib>Stephenson, D</creatorcontrib><creatorcontrib>Mohs, R</creatorcontrib><creatorcontrib>Lalonde, R</creatorcontrib><creatorcontrib>Sinha, V</creatorcontrib><creatorcontrib>Wang, Y</creatorcontrib><creatorcontrib>Brown, D</creatorcontrib><creatorcontrib>Isaac, M</creatorcontrib><creatorcontrib>Vamvakas, S</creatorcontrib><creatorcontrib>Hemmings, R</creatorcontrib><creatorcontrib>Pani, L</creatorcontrib><creatorcontrib>Bain, LJ</creatorcontrib><creatorcontrib>Corrigan, B</creatorcontrib><creatorcontrib>Alzheimer's Disease Neuroimaging Initiative</creatorcontrib><creatorcontrib>Coalition Against Major Diseases</creatorcontrib><creatorcontrib>Alzheimer's Disease Neuroimaging Initiative for the Coalition Against Major Diseases</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Clinical pharmacology and therapeutics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Romero, K</au><au>Ito, K</au><au>Rogers, JA</au><au>Polhamus, D</au><au>Qiu, R</au><au>Stephenson, D</au><au>Mohs, R</au><au>Lalonde, R</au><au>Sinha, V</au><au>Wang, Y</au><au>Brown, D</au><au>Isaac, M</au><au>Vamvakas, S</au><au>Hemmings, R</au><au>Pani, L</au><au>Bain, LJ</au><au>Corrigan, B</au><aucorp>Alzheimer's Disease Neuroimaging Initiative</aucorp><aucorp>Coalition Against Major Diseases</aucorp><aucorp>Alzheimer's Disease Neuroimaging Initiative for the Coalition Against Major Diseases</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The future is now: Model-based clinical trial design for Alzheimer's disease</atitle><jtitle>Clinical pharmacology and therapeutics</jtitle><addtitle>Clin. Pharmacol. Ther</addtitle><date>2015-03</date><risdate>2015</risdate><volume>97</volume><issue>3</issue><spage>210</spage><epage>214</epage><pages>210-214</pages><issn>0009-9236</issn><eissn>1532-6535</eissn><abstract>Failures in trials for Alzheimer's disease (AD) may be attributable to inadequate dosing, population selection, drug inefficacy, or insufficient design optimization. The Coalition Against Major Diseases (CAMD) was formed in 2008 to develop drug development tools (DDT) to expedite drug development for AD and Parkinson's disease.1 CAMD led a process that successfully advanced a clinical trial simulation (CTS) tool for AD through the formal regulatory review process at the US Food and Drug Administration (FDA) and European Medicines Agency (EMA).</abstract><cop>United States</cop><pub>Blackwell Publishing Ltd</pub><pmid>25669145</pmid><doi>10.1002/cpt.16</doi><tpages>5</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0009-9236 |
| ispartof | Clinical pharmacology and therapeutics, 2015-03, Vol.97 (3), p.210-214 |
| issn | 0009-9236 1532-6535 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6463482 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete |
| subjects | Alzheimer Disease - drug therapy Clinical Trials as Topic - methods Computer Simulation Drug Approval - legislation & jurisprudence Drug Approval - methods Europe Humans United States United States Food and Drug Administration - legislation & jurisprudence |
| title | The future is now: Model-based clinical trial design for Alzheimer's disease |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-07T12%3A52%3A28IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20future%20is%20now:%20Model-based%20clinical%20trial%20design%20for%20Alzheimer's%20disease&rft.jtitle=Clinical%20pharmacology%20and%20therapeutics&rft.au=Romero,%20K&rft.aucorp=Alzheimer's%20Disease%20Neuroimaging%20Initiative&rft.date=2015-03&rft.volume=97&rft.issue=3&rft.spage=210&rft.epage=214&rft.pages=210-214&rft.issn=0009-9236&rft.eissn=1532-6535&rft_id=info:doi/10.1002/cpt.16&rft_dat=%3Cproquest_pubme%3E1657325950%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1657325950&rft_id=info:pmid/25669145&rfr_iscdi=true |